Abstract 75P
Background
A parallel deep learning network framework for whole-body bone scan image analysis Whole-body bone scan image analysis in nuclear medicine is a common method assisting physicians in bone metastases detection of cancer. As the increasing need for diagnostic examinations in the huge and elderly population in China, physicians are facing a significant growth of workload but must still manage to read the diagnostic images carefully and avoid errors in interpretation. It is crucial to develop a clinical decision support tool in assisting physicians in their clinical routine.
Methods
In this study, we proposed a parallel deep learning network framework for bone-scan interpretations of the presence or absence of bone metastases. The whole-body bone scans (anterior and posterior views) of 707 patients who are suspected bone metastatic disease were studied. The physicians were asked to classify each case for the presence or absence of bone metastasis manually. Each bone scan image was automatically segmented into 26 different anatomical regions of homogeneous bones based on the skeletal frame. The corresponding 26 deep learning networks made a diagnosis by inspecting each region and searching for abnormal lesion activity simultaneously. To estimate the performance of each anatomical sub-region identification models, a ten-fold cross testing scheme was applied where the data set was divided into ten parts of equal size randomly.
Results
The sensitivity, specificity and the mean number of false lesions detected were adopted as performance indices to evaluate the proposed model. The best sensitivity and specificity of an individual network corresponding to each sub-region are 99.9 % and 97.3% respectively. The overall mean sensitivity and specificity of the parallel model are 99.2% and 71.8% respectively, as well as 2.0 false detections per patient scan image within millisecond.
Conclusions
With an extremely high sensitivity, specificity and a low false lesions detection rate, this proposed parallel deep learning network model is demonstrated as useful for detecting metastases in bone scans. Our proposed framework appears to have significant potential as a clinical decision support tool in assisting physicians in their clinical routine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
X. Pu: Full / Part-time employment: University of Electronic Science and Technology of China; Full / Part-time employment: University of Electronic Science and Technology of China; Full / Part-time employment: University of Electronic Science and Technology of China. G. Tang: Full / Part-time employment: West China University Hospital, Sichuan University. K. Cai: Research grant / Funding (institution): School of Computer Science and Engineering, University of Electronic Science and Technology of China. Y. Huang: Research grant / Funding (institution): College of Computer Science, Sichuan University. M. Ping: Research grant / Funding (institution): School of Computer Science and Engineering, University of Electronic Science and Technology of China. Z. Peng: Research grant / Funding (institution): Big Data Research Center, University of Electronic Science and Technology of China. H. Qiu: Full / Part-time employment: School of Computer Science and Engineering, University of Electronic Science and Technology of China.
Resources from the same session
508P - Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous carcinoma: A phase II study
Presenter: Jinliang Wang
Session: Poster display session
Resources:
Abstract
525P - Retrospective analysis of outcomes of cisplatin and irinotecan combination chemotherapy for unresectable thymic carcinoma
Presenter: Akito Fukuda
Session: Poster display session
Resources:
Abstract
524P - A study in recurrent small cell lung cancer patients, comparing weekly paclitaxel, irinotecan and temozolomide in second-line: A prospective study from a south Indian tertiary cancer hospital
Presenter: LALATENDU MOHARANA
Session: Poster display session
Resources:
Abstract
505P - PD-L1 expression in ALK rearranged NSCLC: All questions answered?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
487P - Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
492P - Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer
Presenter: Heekyung Ahn
Session: Poster display session
Resources:
Abstract
513P - Phase II study of vitamin B12 and folate supplementation for patients undergoing chemotherapy with pemetrexed
Presenter: Shingo Kitagawa
Session: Poster display session
Resources:
Abstract
493P - Is exon 19 deletion different from exon 21 mutation in advanced non-small cell lung cancer: A single centre experience
Presenter: Sarita Shrivastva
Session: Poster display session
Resources:
Abstract
494P - Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
Presenter: Chee Shee Chai
Session: Poster display session
Resources:
Abstract
517P - High BRCA1 expression is independently correlated with decreased overall survival in lung adenocarcinoma: Evidence from meta and bioinformatics analyses
Presenter: Fengzhu Guo
Session: Poster display session
Resources:
Abstract